Pediatric Solid Tumors - Healing Genes

Pediatric Solid Tumors

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors

Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Solid Tumors Of Pediatric Origin In Children And Young Adults

Phase 1


Doctors at the University of Texas MD Anderson Cancer Center seek pediatric patients with solid tumors after receiving chemotherapy (cyclophosphamide and etoposide) to trial the use of donated (allogeneic) natural killer (NK) immune cells that target and may help to control tumors. The trial seeks to determine best doses of NK cells.

  • Malignant Neoplasms of Bone and Articular Cartilage
  • Malignant Neoplasms of Female Genital Organs
  • Malignant Neoplasms of Independent (Primary) Multiple Sites
  • Malignant Neoplasms of Lip Oral Cavity and Pharynx
  • Malignant Neoplasms of Male Genital Organs
  • Malignant Neoplasms of Mesothelial and Soft Tissue
  • Malignant Neoplasms of Thyroid and Other Endocrine Glands
  • Malignant Neoplasms of Urinary Tract
  • Melanoma and Other Malignant Neoplasms of Skin

Study participants will receive 1 of 2 dose levels of NK cells after chemotherapy, then be followed for at least 30 days.


  • Be 12 Months to 40 Years old
  • Not have primary tumors of the central nervous system
  • Be willing to use contraception during the study, if sexually active
  • Match a cord blood donor at a 4, 5, or 6/6 HLA class I (serological) and HLA class II (molecular) antigens


  1. Screening to confirm acceptance to the study.
  2. Participants assigned to a dose level of NK cells based on when study is joined.
  3. Participants receive chemotherapy (cyclophosphamide and etoposide) by vein over about 30 minutes on Days 1-5. Participants then receive NK cells by vein on Day 8.
  4. Mesna (a protective medicine accompanying chemo) will start with dose prior to cyclophosphamide and then 3 and 6 hours after each dose for total of at least 80% of cyclophosphamide dose.
  5. Follow up will continue for at least 30 days after discharge.


The study will take place at the University of Texas MD Anderson Cancer Center. Map.

Contact: Jessica S. Foglesong, MD  |  713-792-6620  |  [email protected]



M.D. Anderson Cancer Center


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader